HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FTC: All Advertisers Should Heed Lessons From “Operation Full Disclosure”

This article was originally published in The Tan Sheet

Executive Summary

On the heels of FTC’s “Operation Full Disclosure,” which resulted in 60 warning letters, commission officials advise all advertisers to pay close attention to their disclosures and ensure they are clear and conspicuous. The initiative included review of 1,000 national television and print ads, and the agency says it will continue to monitor the advertising landscape for inadequate disclosure use.

You may also be interested in...



No Hiding Bogus Coronavirus Claims From US Regulators In Social Media Or With Vague Terms

“I don’t know if there’s a misconception that a different set of adverting rules apply to social media," says FTC attorney Christine DeLorme during FDLI conference. The FTC also sees "a lot of attempts at disclaimers. They might say, ‘Of course there’s no cure for COVID, but...’"

FTC Fines L’Occitane For “Slimming” Claims, Calls For Media “Gut Check”

FTC settles with L’Occitane and three marketers of weight-loss products and launches its “gut check” voluntary media partnership program to help prevent bogus claims. Settlements with the four marketers totaled $33 million.

FTC Brings Dot-Com Disclosure Guide To Social Media, Mobile Era

Revised online advertising disclosure guidelines detail FTC’s expectations for how advertisers should craft disclosures in the world of social media and mobile devices.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS139557

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel